Journal of Clinical Oncology
Articles in this Issue
A phase I study of pomalidomide and nivolumab (Pom/Nivo) in patients with virus-associated malignancies with and without HIV.
2663 Background: Up to 15% of cancers worldwide are associated with oncogenic viruses and disproportionately affect people...
Phase 2 study of adjuvant botensilimab in combination with balstilimab in patients with microsatellite-stable colorectal cancer and persistent circulating tumor DNA following surgery and chemotherapy.
TPS3689 Background: In patients with localized microsatellite stable (MSS) colorectal cancer (CRC), detection of circulati...
Validation of an AI-based clinical decision support system for guideline-concordant prostate cancer treatment at a Brazilian cancer center.
1605 Background: Clinical decision support systems (CDSS) based on large language models may improve adherence to evidence...
Genomic profiling to define molecular drivers of colorectal neuroendocrine carcinoma subtypes.
3666 Background: Neuroendocrine carcinoma (NEC) is a rare and aggressive subtype of colorectal cancer (CRC), often arising...
Identifying high-risk cytogenetic subgroups in multiple myeloma using large language artificial intelligence models.
7523 Background: The Revised International Staging System (R-ISS) is the clinical standard for risk stratification in mult...
Predicting response to <sup>177</sup> Lu-PSMA-617 in metastatic prostate cancer (mPC) using plasma-derived extracellular vesicles (EVs).
5068 Background: 177 Lu-PSMA-617 (LuPSMA) is a groundbreaking therapy for mPC, but biomarkers are urge...
Nivolumab + relatlimab (NIVO + RELA) in advanced melanoma: 5-year update of RELATIVITY-047.
9532 Background: NIVO + RELA improved progression-free survival (PFS) vs NIVO in patients (pts) with advanced melanoma in...
T-cell receptor (TCR) repertoire dynamics of response to neoadjuvant chemo-immunotherapy in triple- negative breast cancer (TNBC).
e12660 Background: Neoadjuvant pembrolizumab plus chemotherapy is the current standard for cT2N0-3 TNBC, yet ~40% of patie...
Tirzepatide-induced lipid metabolic remodeling in relation to clonogenicity and migration in colorectal cancer cells: An <i>in vitro</i> and <i>in silico</i> approach.
e15561 Background: Glucagon-like peptide-1 (GLP-1)–based therapeutics have attracted increasing attention beyond metabolic...
Bispecific antibodies in the treatment of relapsed refractory multiple myeloma: A meta analysis.
e19529 Background: Relapsed/refractory multiple myeloma (RRMM) includes relapse after response orprogression within 60 day...
A comparison of data-processing methods to support patient matching to oncology clinical trials.
e13651 Background: To pre-screen and match patients to trials at scale, technology tools are needed to support human workf...
Healthcare resource use (HCRU) intensity prior to cancer diagnosis and real-world outcomes in early-stage cancers.
1644 Background: Choosing Wisely initiatives aim to reduce futile care by emphasizing the role of clin...
Using stage-matched genomic analysis to support molecular similarity of unknown-primary Merkel cell carcinoma and identify ARID1B as a prognostic marker.
9584 Background: Merkel cell carcinoma (MCC) can present as nodal disease without an identifiable cutaneous primary, terme...
Cardiovascular outcomes of durvalumab versus pembrolizumab in gastric cancer: A propensity-matched TriNetX analysis.
e24017 Background: Immune checkpoint inhibitors targeting the PD-1/PD-L1 axis are increasingly incorporated into gastric c...
FLT3 inhibitors across the allogeneic transplant continuum in <i>FLT3</i> -mutated acute myeloid leukemia: A systematic review and meta-analysis.
e18523 Background: FLT3-mutated AML (30% of cases) carries a high relapse risk despite allogeneic hematopoietic stem cell...
Neoadjuvant PD-1 inhibitor plus paclitaxel, pingyangmycin, and platinum-based chemotherapy (4P therapy) as a bladder-sparing strategy for high-risk non–muscle-invasive/muscle-invasive bladder cancer: A retrospective cohort study.
e16606 Background: To evaluate the efficacy and safety of neoadjuvant PD-1 inhibitor plus paclitaxel, pingyangmycin, and p...
Quality improvement: Enhancing family history documentation for invasive cancer patients in a community oncology clinic.
e23284 Background: Accurate collection and documentation of family history in patients diagnosed with invasive malignancie...
Clinical and genetic characteristics of MSI-high versus MSS gastric cancer patients: A single-institution experience.
e16091 Background: Microsatellite instability-high (MSI-H) gastric cancers (GC) are unique in genotype and have shown to a...
Neoadjuvant pyrotinib plus trastuzumab combined with chemotherapy for HER2+/HR+ early breast cancer: A multicenter phase 2 trail.
e12641 Background: HER2+/HR+ early breast cancer has a lower pathological complete response (pCR) rate after neoadjuvant t...
Assessing the relationship between event-free and overall survival in the era of perioperative chemoimmunotherapy in gastroesophageal cancers.
e16135 Background: Perioperative chemoimmunotherapy is emerging as a global standard for non-metastatic gastroesophageal c...
Enterprise-wide implementation of multicancer detection testing across a large academic health system.
10578 Background: Multicancer detection (MCD) testing using cell-free DNA methylation patterns is a novel blood-based appr...
Development and validation of a preoperative pathological risk prediction model for thymic tumors: A retrospective multicenter diagnostic study.
8122 Background: The preoperative diagnosis of thymic tumors currently relies on preoperative CT data and the experience o...
Fecal microbiota transplantation to reverse resistance to TKI plus PD-1 inhibitors in unresectable hepatocellular carcinoma: A phase 2 clinical trial.
e16205 Background: Tyrosine-kinase inhibitors (TKIs) and immune-checkpoint inhibitors (ICIs) improve survival in unresecta...
From manual to AI-assisted: Improving infusion scheduling in a high-volume cancer center.
e23297 Background: Efficient use of infusion center resources is critical for high-volume cancer centers, yet infusion sch...
MUC5AC-driven transcriptional reprogramming for stratification of pancreatic ductal adenocarcinoma by immune suppression and stromal remodeling.
4194 Background: Mucin 5AC (MUC5AC) is aberrantly expressed in pancreatic ductal adenocarcinoma (PDAC) and associated with...